CDC recommends yearly chlamydia testing for:
- Sexually active women under 25 years of age. Retesting should be done three months after treatment.
- Sexually active women 25 years of age and older if if they have a new partner, or if they have an increased chance of being exposed to chlamydia (e.g. have more than one sex partner, a sex partner with concurrent partners, use condoms inconsistently when not in a mutually monogamous relationship, have a history of transactional sex work, or have a history of incarceration). Retesting should be done three months after treatment.
- Men who have sex with men (MSM)
- People living with HIV
Additional recommendations include:
- Rectal testing for some women based on reported sexual behaviors and exposure, as well as for MSM
- Testing for in the first trimester for pregnant women younger than 25 and for older pregnant women who have a new partner or an increased chance of exposure to chlamydia (see above). Retesting should be done in the third trimester.
- More frequent testing (every 3 to 6 months) for MSM on PrEP, with HIV infection, or if they or their sex partners have multiple partners.
- For transgender or gender diversion persons, screening recommendations should be adapted based on anatomy.
CDC recommends yearly gonorrhea testing for:
- Sexually active women under 25 years of age. Retesting should be done three months after treatment.
- Sexually active women 25 years of age and older if if they have a new partner, or if they have an increased chance of being exposed to gonorrhea (e.g. have more than one sex partner, a sex partner with concurrent partners, use condoms inconsistently when not in a mutually monogamous relationship, have a history of transactional sex work, or have a history of incarceration). Retesting should be done three months after treatment.
- Men who have sex with men (MSM)
- People living with HIV
Additional recommendations include:
- Rectal and pharyngeal (throat) testing for some women based on reported sexual behaviors and exposure, as well as for MSM
- Testing for in the first trimester for pregnant women younger than 25 and for older pregnant women who have a new partner or an increased chance of exposure to chlamydia (see above). Retesting should be done in the third trimester.
- More frequent testing (every 3 to 6 months) for MSM on PrEP, with HIV infection, or if they or their sex partners have multiple partners
- For transgender or gender diversion persons, screening recommendations should be adapted based on anatomy.
The CDC recommends that everyone aged 13 to 64 should be tested for HIV at least once. Most HIV is transmitted by the 25% of infected people who do not realize they are infected.
Sexually active MSM may benefit from more frequent HIV testing (e.g. every 3 to 6 months).
All pregnant women should be tested at their first prenatal visit. Women who may be more likely to be exposed to HIV (due to having having STIs during pregnancy, having multiple sex partners during pregnancy, having a new sex partner during pregnancy, living in an area with high HIV prevalence, or having partners with HIV) should be retested in their third trimester.
CDC recommends syphilis testing for:
- All pregnant women at their first prenatal visit. Women who have an increased chance of being exposed to syphilis (due to substance use, STIs during pregnancy, multiple partners, a new partner, or a partner with STIs) should retest at 28 weeks of pregnancy. Syphilis during pregnancy can lead to miscarriage, low birth weight, premature delivery or stillbirth, death shortly after birth, and/or lifelong health issues.
- Women and men who have a history of incarceration or transactional sex work or who live in an area where syphilis rates are high.
- Men who have sex with women and are age younger than 29.
Annual testing is recommended for:
- Men who have sex with men (MSM
- People living with HIV
Human papillomavirus (HPV) screening is recommended for anyone with a cervix, starting at either age 21 or 25. CDC recommends:
- Screening with a Pap test every three years from age 21 to 29
- Screening with either a Pap test every three years, HPV primary test every five years, or co-test (Pap and HPV testing together) every five years
The American Cancer Society guidelines, updated in December 2025, are slightly different. They recommend primary HPV testing, every 5 years, as the preferred screening option, starting at age 25. Beyond this option, they recommend:
The best type of screening is whatever type is available to you. Most cases of cervical cancer are in people who have fallen behind these screeneing schedules. Cervical cancer can be preventing by early diagnosis and treatment. The HPV vaccine can also prevent cervical cancer and other types of HPV-related cancer.
Herpes testing isn’t recommended routinely like other STIs (such as chlamydia and gonorrhea). It is only people who have symptoms or concerns, such as a partner with herpes.
CDC says that blood tests might be useful for people who:
- have genital symptoms that could be related to herpes
- have (or have had) a sex partner with genital herpes
- have been told by a provider that they have signs of herpes but need a test to confirm it
A blood test will tell whether or not a person has HSV-1, HSV-2, or both. If a person tests positive for HSV-2, it is virtually always a genital infection. If a person tests positive for HSV-1, it may be either an oral or genital infection. The blood test can only identify the virus type, not the site of the infection.
When a person has active herpes lesions (a.k.a. blisters, sores), a swab can be taken and tests can done that can detect the virus directly. A Nucleic Acid Amplification Testing (NAAT) can identify the specific herpes virus type someone is infected with (HSV-1 or HSV-2).